Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.46 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9280678 | 0.89 | GNAI3 (0.57) | POLBL3MBTL1NPC1GNAI3GNAO1 | |
| SCHEMBL9428505 | 0.87 | GNAI3 (0.64) | POLBL3MBTL1NPC1GNAI3GNAO1 | |
| SCHEMBL10757141 | 0.86 | GNAI3 (0.67) | POLBL3MBTL1NPC1GNAI3GNAO1 | |
| SCHEMBL5606242 | 0.86 | GNAI3 (0.67) | POLBL3MBTL1NPC1GNAI3GNAO1 | |
| SCHEMBL10535735 | 0.86 | GNAI3 (0.67) | POLBL3MBTL1NPC1GNAI3GNAO1 | |
| SCHEMBL10535769 | 0.86 | GNAI3 (0.67) | POLBL3MBTL1NPC1GNAI3GNAO1 | |
| SCHEMBL10537382 | 0.86 | GNAI3 (0.67) | POLBL3MBTL1NPC1GNAI3GNAO1 | |
| SCHEMBL9427599 | 0.86 | GNAI3 (0.67) | POLBL3MBTL1NPC1GNAI3GNAO1 | |
| SCHEMBL27429183 | 0.85 | NPC1 (0.48) | POLBL3MBTL1NPC1GNAI3GNAO1 | |
| SCHEMBL4259604 | 0.84 | L3MBTL1 (0.54) | POLBL3MBTL1NPC1LMNAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207726-A1 | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2020-07-02 | — | — | US | disclosed |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| EP-1765780-A1 | PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006004195-A1 | PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2006-01-12 | — | — | WO | disclosed |
| EP-1537106-A1 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004014910-A1 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-02-19 | — | — | WO | disclosed |
| US-5102890-A | Anxiolytic agents | RHONE-POULENC SANTE (FR) | 1992-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207726-A1 | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | RORA, RORC, RORB | POLB 4324/4885L3MBTL1 4845/4885NPC1 2694/4885 |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | POLB 1461/4885L3MBTL1 1081/4885NPC1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.